image_news_apr_2016
April 2017

iMed.ULisboa project funded under the Gilead GÉNESE Program 2016

At the ceremony held at the Thalia Theater in Lisbon, on April 6th, 2017, the project “HIV-TRANFERSOME: fusion inhibitor incorporated in transfersomes for transdermal delivery”, led by Quirina dos Santos Costa, iMed.ULisboa investigator from the Host-Pathogen Interactions Group was selected to be funded under the Gilead GÉNESE Program 2016 edition.

This interdisciplinary project includes other researchers from iMed.ULisboa (Andreia Ascenso, Sandra Simões, José Azevedo Pereira),  iBET (Maria Rosário Bronze) and iMM (Filomena Carvalho and Nuno Santos).

The objective of this project is to develop an innovative formulation for transdermal delivery of enfuvirtide (T-20) that is non-invasive, painless and comfortable, with the aim of increasing therapeutic adherence without the inconveniences of the injectable form. The stable formulation is based on lipid nanoparticle-systems specially designed for topical (skin) application containing T-20 incorporated into ultra-deformable vesicles, for transdermal delivery. This new concept will bring clear societal and clinical benefits in the treatment of HIV/AIDS infection, namely in improving the quality of life of people living with HIV/AIDS, especially children and older adults.

The project entitled “Role of the ectosomes in the dissemination of HIV infection in CNS and their contribution to HIV-associated dementia” also led by iMed.ULisboa investigators was selected to be funded under the same Gilead GÉNESE Program 2016 edition.